Another particularly interesting agent in the field of DCM therapy is pioglitazone, an insulin-sensitizer from the thiazolidinedione (TZD) class of nuclear peroxisome proliferator-activated receptor γ-agonists, which decreases insulin resistance in the liver and peripheral tissues. The gene discussed is INS; the disease is Insulin resistance.